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Abstract
Background: In the development of new drugs for severe asthma, it is a challenge from an ethical point of view
to randomize severe asthma patients to placebo, and to obtain long-term safety data due to discontinuations. The
aim of this study was to evaluate the feasibility of using electronic health record (EHR) data to create a real-world
reference population of uncontrolled asthmatic patients to supplement the concurrent control/placebo group in
long-term studies of asthma.
Methods: EHR data from 36 primary care centres and a University hospital in Sweden were linked to Swedish
mandatory health registers (2005–2013), creating a population covering 33 890 asthma patients, including data
on co-morbidities, risk factors and laboratory/respiratory measurements. A severe asthma EHR reference cohort was
established. We used logistic regression to estimate the propensity score (probability) of each RCT or EHR patient
existing in the EHR cohort given their covariates.
Results: We created an EHR-derived reference cohort of 240 patients, matching the placebo group (N = 151) in
an RCT of severe asthma. The exacerbation rate during follow-up in the EHR study population was 1.24 (weighted)
compared to 0.9 in the RCT placebo group. Patients in the EHR cohort were of similar age as in the RCT placebo
group, 50.6 years versus 50.1 years; had slightly higher body mass index 27.0 kg/m2 versus 27.3 kg/m2; and
consisted of 40% versus 34% males.
Conclusions: The results indicate that EHRs provide an opportunity to supplement the control group in RCTs of
severe diseases.
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Background
Asthma is a common but complex heterogeneous chronic
inflammatory disease of the airways, which presents with
variable symptoms of cough, breathlessness, and wheeze,
with episodic acute worsening of symptoms known as
exacerbations, particularly in severe asthma [1]. The
prevalence of asthma in Sweden is 8-10% [2] and
pharmacological treatment to relieve symptoms and main-
tain optimal lung function is required, but despite various
treatment options, a large proportion of patients have
asthma that remains uncontrolled [3]. These patients have
an increased risk of developing severe exacerbations, suf-
fer from a poor quality of life, and pose a high economic
healthcare burden [3].
There is a broad spectrum of novel therapeutic agents
currently under development for the treatment of severe
asthma. Development of a new drug requires extensive
documentation of effectiveness and safety, usually by com-
parison with a placebo control group in a RCT. When the
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indication involves severe asthma, it may be an ethical
challenge to randomize patients to a long-term safety
follow-up in a control group receiving placebo [4].
Difficulties enrolling severe asthma patients to long-
term placebo controlled trials may have a negative im-
pact on the development time of new innovative drugs,
a disadvantage to patients in need [5]. Moreover, it may
be difficult keeping severe asthma patients in the
placebo arm of a long-term safety study data due to
discontinuations [6]. Implications include for example
the inability to contextualise any findings in the active
control arm.
In parallel, clinical research is on the threshold of a
new era in which electronic health records (EHR) are
gaining an important novel supporting role [7]. The
transition into EHRs has been far from uniform in dif-
ferent parts of the world and has not mirrored general
information communication technology (ICT) develop-
ments. In some regions, including Scandinavia and the
UK, electronic systems were first adopted by primary
care, whereas in others, the development was led by uni-
versity clinics in large hospitals [8]. Whilst EHRs used
for routine clinical care have some limitations at present,
new improved systems and emerging research infra-
structures are being developed to ensure that EHRs can
be used for secondary purposes such as clinical research,
including the design and execution of clinical trials for
new medicines [9]. Still, given the poor quality of many
legacy EHR systems, it is not surprising that their use
for clinical research has been limited. In many cases,
special disease registers at a regional or national level
(often termed quality registers) have been created with
special reporting outside the normal clinical record, pri-
marily to support quality improvement in health care
systems but also to serve research purposes. Some coun-
tries have invested substantially in such registries; for
example, Sweden’s ‘national quality registers’ include
more than 100 disease conditions on a national scale
and collect high quality data with coverage that may be
near 100% of all cases for some of these conditions [10].
This has created much valuable data, many international
publications and a significant impact on the practice of
medicine. However, the registry structures are inflexible
and create significant work, even if EHR extracts using
modern standards can partially automate registry data
capture, as has been demonstrated for the Swedish Heart
Failure Register and the Swedish National Diabetes
Register [11].
Another common health data source for clinical re-
search, especially in the US, is health insurance adminis-
trative data, or claims data. Claims data include diagnostic
information, treatments given, and providers used, in
addition to a variable number of financial measures [12].
This makes them appealing to researchers as they offer
numerous advantages such as anonymous, plentiful, inex-
pensive, and widely available information in electronic for-
mat. However, because these data systems were developed
for administrative purposes they often lack quality and
adequate measures needed for clinical research. Moreover,
claims data in many countries are limited to patients that
can afford health insurance thereby creating a socio-
economic bias [13].
Currently, we see an increasing pace of implementation
of modern quality-controlled EHRs with growing evidence
that EHRs can support clinical research including but
certainly not limited to clinical trials for new medicines
(e.g., optimizing and validating clinical protocols and
supporting identification of investigator hospital sites)
[7]. To further explore the value of EHR data for clin-
ical research it is important to evaluate to what extent
EHR systems have reached the maturity to provide
more integrated support to randomized clinical trials
(RCT). One such example is the use of EHR data to
create a real-world reference population of patients to
supplement the control/placebo group in long-term
studies of severe diseases.
The aim of this propensity score weighted, retrospect-
ive, observational cohort study was to evaluate the
feasibility of creating an EHR/registry-based reference
cohort comparable to the placebo group of a previously
completed randomized clinical trial (RCT) in severe
asthma.
Methods
Study design, protocol and data sources
This was a propensity score weighted, retrospective study
where the placebo group population and its outcome in
an RCT was compared to an observational cohort, link-
ing data from national mandatory Swedish registries to
primary care EHR data.
The Swedish National Board of Health and Welfare
performed data linkage and the Department of Medical
Sciences, Respiratory Medicine at Uppsala University,
Sweden managed the linked database.
Thirty-six centres and one university hospital were
included, with a catchment area covering 4% of the
Swedish population. No stratification of primary health-
care centres was performed, but effort was made to re-
flect Swedish asthma healthcare by selection of centres
that covered a representative sample of the Swedish
asthma population, by a mix of rural and urban areas,
public and private providers, and centre size [14]. EHR
data (e.g., date of birth, gender, diagnoses by ICD-10
codes, number of primary healthcare centre contacts, lung
function assessments, prescribed medications, exacerba-
tions, and laboratory variables) were extracted using an
established software system (Pygargus Customized eXtrac-
tion0, Program, CXP™) [15].
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Data were also extracted retrospectively from Swedish
national registers, covering mandatory individual health
data on a full population level. Data regarding morbidity
and mortality were collected from the National Patient
Register, including inpatient hospital care (admission
and discharge dates, main and secondary diagnoses
specified by ICD-10 code) and outpatient hospital care
(number of contacts, diagnoses), and the Cause of Death
register, including date and cause[s] of death, respect-
ively. Data on drug prescriptions from hospital and pri-
mary care were collected from the Swedish Prescribed
Drug Register. We were able to follow patients for up to
nine years (2005-2013). The regional ethics committee
in Uppsala, Sweden approved the study protocol.
The base population (primary data set) included males
and females, with a record of drug prescription for ob-
structive pulmonary diseases (Anatomical Therapeutic
Chemical (ATC) code R03) and/or a physician-diagnosed
asthma (ICD-10 code J45-J46) in the primary care setting.
No exclusion criteria were predefined. To preserve patient
anonymity the social security number used to identify
patients was replaced with a study ID number prior to
further data processing. Selection of patients from the
EHR base population into the EHR study cohort consisted
of a two-step approach: We first extracted data from
EHRs (n = 33890) and sent it to the Swedish National
Board of Health and Welfare, which linked this database
to the pre-defined national registers (e.g., patient, pre-
scription of drug, and cause of death registries) [16]
(Fig. 1). We then needed to identify patients (n = 240) eli-
gible for inclusion in a predefined RCT study using the
RCT inclusion and exclusion criteria.
RCT study population
To compare to the EHR study cohort, a data set of de-
identified RCT placebo data was derived from a com-
pleted AstraZeneca-sponsored randomised, double-blind,
placebo-controlled, parallel-group, multicentre, phase 2b
study in severe asthma [17]. A total of 452 patients were
randomly assigned (1:1) to one of two dosing regimen
groups and further randomised (2:1) to receive tralokinu-
mab or placebo. For the current PACEHR study, the entire
RCT population (n = 452) is used to represent the placebo
group for baseline (index date) comparisons; since the
study is randomized, they represent a larger sample of the
same patients as the placebo group at baseline. For out-
come assessments, the RCT placebo data set used con-
sisted of results from the 151 placebo patients in this
study.
The RCT study design consisted of a 5 week screen-
ing and run-in period, a 48 or 50 week treatment
period (depending on dosing regimen), and a 22 week
safety follow-up period. Enrolled patients were aged
18–75 years with severe uncontrolled asthma, consist-
ent with the European Respiratory Society and Ameri-
can Thoracic Society definition [18]. Patients were
receiving high dose inhaled corticosteroids (total daily
dose >500 μg fluticasone dry powder inhaler or equiva-
lent via metered dose inhaler) plus a long acting beta
agonist (LABA) at least 30 days before visit 1, and had
at least two, but no more than six, exacerbations in the
previous 12 months. The primary outcome variable was
the annual asthma exacerbation rate at week 52. Add-
itional secondary outcomes included lung function end-
points, Asthma Control Questionnaire-6 and Asthma
Quality of Life Questionnaire at week 52 [17].
Outcome variables
For this study, the definitions for outcome variables were
the same as those used in the RCT study. Asthma
exacerbation was defined according to established cri-
teria, which consisted of an increase in asthma symp-
toms resulting in use or increase in dose of systemic
corticosteroids for three or more consecutive days [18].
Fig. 1 Data flow for creating the EHR placebo population
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The number of exacerbations was evaluated during a 12-
month follow up period starting from the index date in
the EHR study cohort and from the date of randomization
in the RCT study population (Fig. 2). Lung function was
determined by spirometry and expressed as the percent of
predicted normal forced expiratory volume in one-second
(FEV1).
Statistical analysis
Conceptually, the patients included in the RCT were
assumed to constitute a sample from a population of
eligible patients, where the actual sampling probability
is unknown and varies between patients depending on
patient characteristics. This probability can be opera-
tionalized as a propensity score [19, 20], although in
the current analysis, the compared study populations
are defined by inclusion or not in an RCT, as opposed
to being exposed or not to a certain treatment. As the
aim was to use the patients in the EHR population as a
control (comparison) group, the estimated outcomes
in the EHR population were adjusted for the selection
probabilities derived from the propensity score model.
Specifically, to accomplish this we weighted the out-
come estimate with the inverse of the probability for
each EHR patient of being an RCT patient [21, 22].
We used a logistic regression model on the combined
dataset of RCT placebo patients and EHR reference
cohort patients, with inclusion in RCT yes/no as out-
come, to estimate the selection probabilities, and in-
cluding age, gender, BMI, GINA classification, FEV1
and the number of pre-index exacerbations as inde-
pendent variables [23].
We used a weighted Poisson regression model includ-
ing age to estimate the exacerbation rate. To estimate
the average FEV1 we used the arithmetic mean at each
visit in the RCT and both unweighted and weighted
arithmetic means during the whole 12-month follow up
period in the EHR population. Confidence intervals for
the weighted average, considering weights, were deter-
mined using robust standard errors. The analysis was
done using SAS (V.9.4, SAS Institute Inc. North
Carolina, USA) and R for Windows (V. 3.2.3, R Foun-
dation) statistical software.
For the selection of EHR patients, we evaluated
each patient with respect to inclusion criteria in the
RCT at regular time points 30 days apart. At each of
these time points, we considered the patient age and
number of exacerbations for the 12 months prior to
that time point. A patient was considered eligible at
the time point if the age was between 18 and 75 and
the patient had two or more pre-index exacerbations.
If the patient were eligible at more than one time
point, one of the time points was randomly selected
as the index date.
Results
Patients in the EHR study cohort were of similar age as
the patients in the RCT population, mean (SD) 50.3
(14.8) years versus 50.1 (12.3) years, had slightly higher
body mass index (BMI), 28.0 (5.8) kg/m2 versus 27.3
(4.9) kg/m2, and consisted of 31.7% versus 34.4% males.
The patients in the EHR study cohort were more likely
to be in GINA 5, 42.1% compared to 17.1% in the RCT
study population and had on average 3.0 exacerbations
during the 12 months preceding the index date com-
pared to 2.6 in the RCT population. The mean FEV1
percentage was 84.1% in the EHR study cohort and
68.7% in the RCT population. Details on comorbidities,
medications used at baseline index date and laboratory
variables for the EHR population are available in the
appendix.
Applying weights increased the similarity between the
RCT and the EHR patients on baseline characteristics,
with the most prominent effect on pre-bronchodilator
Fig. 2 Index date methodology for randomising the EHR population
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FEV1 (% predicted) and the proportion of GINA 5 pa-
tients. Results show for the EHR population a weighted
average (SD) pre-bronchodilator FEV1 (% predicted) of
63.1 (31.8), compared to the unweighted average 84.1
(19.0) and in the proportion of GINA 5 patients a
weighted percentage of 13.3% against the unweighted
42.1% (Table 1).
The distribution of the estimated propensity scores
indicated that the unweighted EHR population and
the RCT population are not directly comparable
(Fig. 3) although the main assumption of no patients
having propensity scores of zero or one is fulfilled
(Table 2).
The one year exacerbation rate in the placebo group
of the RCT was 0.9 [95% CI 0.76, 1.08] and 1.86 [95%
CI 1.70, 2.05] in the EHR study population. The
weighted exacerbation rate in the EHR study popula-
tion becomes 1.24 [95% CI 0.94, 1.63], which is sub-
stantially closer to the exacerbation rate in the placebo
group in the RCT (Table 3).
The patients in the RCT had spirometry performed
at each visit. The average FEV1 ranged from 68.3
[65.7, 71.0] (mean with 95% CI) at the baseline visit
to 71.5 [68.6, 74.4] (mean with 95% CI) at visit 13 at
52 weeks. Only 74 EHR patients had spirometry
performed during the 1-year post-index period. The
average FEV1 for these patients was 78.2 [72.7, 83.7]
(mean with 95%CI). The corresponding weighted
average with 95% CI was 68.0 [58.3, 77.8] which again
is much closer to what is observed in the placebo
group of the RCT.
In the RCT population, FEV1 was observed under
controlled conditions at scheduled visits leading to a
large number of repeated observations per patient. In
the EHR population FEV1 was observed as part of rou-
tine spirometry as needed by the treating physician and
hence not all patients in the EHR population have any
observations on FEV1 during the 12-months post index
period and those who do have one or perhaps two ob-
servations (Appendix 1).
Discussion
In the present retrospective, observational cohort study
based on a population of 33 890 asthma patients, with
up to nine years of follow-up in Sweden, we showed
that it is technically feasible to create a reference co-
hort (N = 240) which has reasonable similarity to an
RCT placebo group (N = 151) in severe asthma. This
was accomplished both by finding an adequate number
of patients and by creating high data quality (i.e., cap-
turing the key inclusion/exclusion criteria to ensure
reasonable comparability). We used asthma exacerba-
tion frequency, which also was the primary outcome in
the RCT study, as a key indicator to evaluate the com-
parability achieved between the RCT and EHR placebo
groups.
Previous research has been successful to create high
quality data from registries in the area of asthma [24].
To our knowledge, this study is the first to examine
the possibility to mimic a randomized placebo RCT co-
hort based on real world data. A major strength is that
this study is based on a large population sample in a
well-defined geographical area. The weighted analysis
approach proved successful to largely account for dif-
ferences in sampling probability between the RCT and
the EHR patients, as assessed by comparable estimates
of exacerbation rate and FEV1. The uniqueness of this
study is the actual successful extraction, and forma-
tion, of a de-identified data set, linking Swedish pri-
mary care medical records data with a number of
Swedish National health registers, and then to provide
a pool of patients which mimic the characteristics of a
RCT placebo group in severe asthma. The high quality
of the registry data allowed us to find the required data
elements.
Creating an EHR population that is analogous to a
RCT placebo population has several difficulties. First, we
had to operationalize the inclusion criteria based on data
that are routinely captured in EHR, as opposed to what
is captured in a Case Report Form (CRF) based on a
study protocol. There can be substantial differences in
Table 1 Descriptive statistics on weighted vs. un-weighted confounders
Variable EHR (unweighted) EHR (weighted) RCT total population
n Mean (SD %) n Mean (SD %) N Mean (SD %)
Age 240 50.3 (14.8) 239 50.6 (23.7) 451 50.1 (12.3)
BMI (kg/m2) 239 28.0 (5.8) 239 27.0 (7.6) 451 27.3 (4.9)
FEV (% predicted) 240 84.1 (19.0) 239 63.1 (31.8) 450 68.7 (18.0)
GINA 5 n (%) 240 101.0 (42.1%) 239 70.0 (13.3%) 451 77.0 (17.1%)
Male n (%) 240 76.0 (31.7%) 239 106.1 (40.1%) 451 155.0 (34.4%)
Neutrophils (unit) 77 6.2(2.8) 77 6.0 (2.8) 426 4.7 (2.0)
One year Pre-index Exacerbations rate 240 3.0 (1.6) 239 2.5 (1.5) 451 2.6 (0.9)
Weighted and unweighted patient characteristics of the EHR population compared to the combined placebo and treatment groups in RCT
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the timing of assessments, as well as in the actual mea-
surements used. Furthermore, patients participating in a
RCT are not in fact as assumed by our method a true
random sample from the population found in an EHR
source. While between subject differences in sampling
probability due to observed variables might be adjusted
for, as was done in this analysis, there can easily be
differences due to unobserved variables. Having access
to detailed information on diseases and medications pre
index from the trial for the RCT patients and from in-
hospital and pharmacy claims registries will increase the
likelihood of successfully adjusting for differences in se-
lection probabilities related to disease severity and co
existing conditions. Other factors such socioeconomic
factors are much harder to account for. While there are
registries containing socioeconomic data such as in-
come, education and ethnicity in terms of country of ori-
gin available in some countries (e.g., Sweden) these data
would rarely be available for the patients in the RCT
even if the study was done in such a country, mainly de-
pending on the strict rules of data integrity surrounding
an RCT.
Lastly, the way that outcome measures are observed
needs to be consistent for the EHR and RCT popula-
tions. There are commonly accepted standards for per-
forming spirometry, but this test is performed less
consistently in regular practice than in an RCT. Conse-
quently, observations on FEV1 in the EHR cohort may
differ from those obtained in the RCT in timing and
frequency. Exacerbations are partly defined by use of
OCS, and the distinction between continuous use and
acute use may not be completely clear in registry data
while it is unambiguously recorded in the case report
form for an RCT.
Questionnaire approaches to assessing patient re-
ported outcomes are commonly used in RCTs but in-
frequently are included in EHRs. Issues like these
might lead to systematic differences in the observed
outcome that are impossible to statistically account for
and for future studies hard clinical endpoints such as
death of other well defined events may be better choice
if relevant.
Fig. 3 Distribution of the estimated probability of being EHR patient vs the RCT population
Table 2 Descriptive statistics of the estimated propensity scores
of EHR and RCT data
Population n Mean SD Min Median Max
RCT 239 0.50 0.24 0.03 0.51 0.95
EHR 450 0.26 0.17 0.03 0.23 0.88
Table 3 Estimated exacerbation rates of RCT and EHR data
Population Analysis Rate Lower 95% CI Upper 95% CI
RCT (placebo) Unweighted 0.90 0.76 1.08
EHR Weighted 1.24 0.94 1.63
EHR Unweighted 1.86 1.70 2.05
Weighted and unweighted exacerbation rates for the EHR population (n = 240)
and unweighted exacerbation rate for placebo arm in the RCT (n = 151)
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The use of actual EHR data linked to various sources,
prescription data and laboratory data including spirometry
data, presents a unique opportunity to create a dataset
that is sufficiently rich to address the difficulties men-
tioned above. Both of the two most important con-
founders, the number of exacerbations during the
12 months preceding the index date and the pre index
FEV1, were captured for a sufficiently large number of
patients, similar to the RCT sample size. However, some
laboratory variables were sparsely collected in the EHR
population and there were difficulties in finding relevant
observations on some of the laboratory variables key to
the RCT, such as neutrophils and eosinophils. This mainly
reflects that these variables only rarely are used in general
clinical practice. Further details of captured data variables
in the EHR reference cohort can be found in Appendix 2.
Limitations
There are several important assumptions that underpin
the analysis. Firstly, the inclusion and exclusion criteria
need to be equivalent. In the RCT placebo cohort, we had
the opportunity to assess pre-randomization variables
according to a specific protocol. In the EHR cohort, the
corresponding criteria had to be operationalized based on
routinely available observations recorded in the EHR.
Therefore, the inclusion criteria may not be equivalent,
which may lead to systematic differences in the RCT and
EHR population.
Secondly, we assumed that the RCT study population
was a random sample conditional on the patient charac-
teristics used to estimate the weights that we used to
create the EHR reference. This is equivalent to the
assumption of “no unobserved” confounders commonly
used in epidemiology. Although capturing data on the
most obvious confounding variables, such as the number
of pre-index exacerbations, pre index GINA classification
and spirometry, we cannot be certain that there are no
unobserved confounders. The analysis technique used
here is also not able to adjust for the notion of a placebo
effect arising from the very participation in an RCT.
Furthermore, we must assume that the outcome meas-
ure is recorded in the same way in the RCT and EHR
population. Exacerbations are partly defined as increased
acute use of OCS, which is difficult to distinguish from
continuous use based on the drug dispense registry. Lastly,
the results for the RCT placebo cohort used in this study
were taken from a large multicentre trial with patients
from 16 countries not including Sweden. The EHR data
used comes from primary care centres in Sweden. Asthma
care in most countries generally follows international
guidelines [23] but asthma prevalence [25], as well as the
placebo exacerbation rate in trials, are known to vary
among countries [26]. These observations may make it
difficult to relate a global RCT to a population in a single
country that was in this case not even represented in the
trial.
Another potential limitation when using EHR data for
creating a reference group is the risk of overestimating
the treatment effect. This is due to the fact that in RCTs
there is often an improvement in the control groups be-
cause the patients have improved asthma care due to
regular visits. Thus the effect in the treatment group is
combination of the improved asthma care and the drug
treatment. This limitation is supported by the fact that
the prevalence of exacerbations was higher in the EHR
groups than the RCT control group.
Further research and opportunities
This study demonstrates the feasibility of capturing high
quality health data in EHRs and offers the possibility of
creating a real-world reference population of uncon-
trolled severe asthma patients to supplement or even po-
tentially replace the control/placebo group in long-term
studies. Results provide evidence for the value of EHR
data to improve the design and interpretation of clinical
trials. Moreover, our results support the opportunities to
conduct registry-based trials or so-called mixed trials
where a placebo cohort can prospectively go alongside a
RCT study especially in disease areas where it is prob-
lematic to assign patients to placebo treatment. For in-
stance long term extension studies are presently often
uncontrolled one-armed designs without an internal ref-
erence. One concern with this study design is unantici-
pated adverse events. Adding an external reference
cohort based on registry data using the technique pre-
sented in this paper may aid the interpretation of such a
finding in this type of study. Further research should val-
idate the methodology within other disease areas. For
the future, the PACEHR approach would render import-
ant value like for example long term safety study for
asthma in which the patient is receiving a biologic agent
in development, a control group is simply not be feas-
ible, or for other diseases like atopic dermatitis. For both
these cases, among others, identifying an appropriate
control group from EHRs to be followed prospectively
would be perfectly suitable and helpful.
Conclusion
This study demonstrate that an adequate large number
of severe uncontrolled asthma patients, comparable to
the placebo group in a RCT, can be found in Swedish
EHRs based on pre-defined criteria for uncontrolled
asthma. Causal inference methodology based on propen-
sity score analysis and weighting methods adjusted for
differences in observed confounders, and can provide a
useful tool to aid the interpretation of RCTs. The results
indicate that EHRs provide an opportunity to supple-
ment, the control group in RCTs of severe diseases.
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Table 4 EHR spirometry data (average FEV1) from RCT & EHR
cohorts
RCT data per visit # N Mean Lower Upper
1 151 68.3 65.7 71.0
3 150 70.2 67.4 73.0
5 145 69.9 67.0 72.9
9 143 69.9 66.9 73.0
13 142 71.5 68.6 74.4
17 137 69.9 66.8 73.0
21 132 70.2 67.0 73.3
25 134 69.4 66.3 72.5
33 129 69.5 66.3 72.7
41 129 70.2 67.0 73.3
49 130 69.4 66.1 72.7
53 129 69.1 65.9 72.3
59 127 70.4 67.4 73.5
67 111 70.4 67.1 73.7
75 77 70.4 65.8 74.9
EHR data N Mean Lower Upper
Unweighted 74 78.2 72.7 83.7
Weighted 73 68.0 58.3 77.8
Table 5 EHR cohort (N = 367): Comorbidity at index
Condition N (%)
Respiratory-related conditions 118 (49.2)
Acute upper respiratory tract infections 161 (67.1)
Chronic bronchitis 11 (4.6)
COPD NA
Asthma NA
Pneumonia and influenza 59 (24.6)
Influenza 4 (1.7)
Pneumonia 58 (24.2)
Other respiratory system diseases 4 (1.7)
Other diseases of the upper respiratory tract 83 (34.6)
Non-allergic 14 (5.8)
Allergic 50 (20.8)
Chronic rhinitis 14 (5.8)
Other relevant conditions 124 (51.7)
Diabetes 13 (5.4)
Type 1 3 (1.3)
Type 2 10 (4.2)
Metabolic Disorders 26 (10.8)
Table 5 EHR cohort (N = 367): Comorbidity at index (Continued)
Hypertensive diseases 56 (23.3)
Ischaemic heart disease 8 (3.3)
Unstable angina NA
Angina pectoris 3 (1.3)
Myocardial infarction 5 (2.1)
Chronic sinusitis 7 (2.9)
Heart failure 1 (0.4)
Malignant neoplasm 4 (1.7)
Cerebrovascular diseases 0 (0.0)
Haemorrhage 1 (0.4)
Cerebral infarction / Stroke 1 (0.4)
Rheumatoid arthritis NA
Polymyalgia rheumatic 56 (23.3)
Anxiety and Depression disorder 28 (11.7)
Anxiety 46 (19.2)
Depression 8 (3.3)




Inflammatory bowel disease 6 (2.5)
Crohn's disease 3 (1.3)
Other acute lower respiratory infections 97 (40.4)
Chronic lower respiratory diseases 4 (1.7)
NA = value not found or zero
Appendix 1
Appendix 2
Table 6 EHR cohort (n = 367): Concomitant medication at index
Treatment n (%)
ASTHMA MEDICATIONS 367 (100.0%)
Inhaled corticosteroids (ICS) 215 (58.6)
Long-acting ß2-agonists (LABA) 124 (33.8)
ICS/LABA combination 208 (56.7)
Adrenergic in combination with anticholinergics 5 (1.4)
Short acting 5 (1.4)
Long acting NA
Leukotriene modifiers (LTRA) 113 (30.8)
Methylxanthines 4 (1.1)
Anti-IgE treatment NA
Short-acting ß2-agonists (SABA) 256 (69.8)
Systemic corticosteroids (OCS) 367 (100.0)
Anticholinergics 21 (5.7)
- Short acting 9 (2.5)
- Long acting 13 (3.5)
Omalizumab NA
PD4 antagonists NA
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